Navigation Links
Old is gold– proved yet another tim

Chloroquine, an antimalarial drug was highly successful in combating the disease when launched in the 1950s.// It soon became useless because of resistance being developed by the malarial parasite.

Scientists have found a way to breathe new life into the drug. It has been found that combining the drug with another preparation, Primaquine, would restore the effect of the original drug.

Malaria is caused by the parasite Plasmodium falciparum and is associated with a significant mortality all over the world, especially in the developing countries.

Chloroquine - which is far cheaper than more modern malaria drugs - works by blocking the way the parasite breaks down human hemoglobin contained in red blood cells. If the haem molecules remain in an uncrystallised form, they are toxic to the parasite, thereby killing it.

On its own, primaquine has no effect on P. falciparum, but it is structurally similar to chloroquine. The right concentration and combination of Primaquine and Chloroquine has been found to be effective on chloroquine-resistant parasites.

It is believed that that the drug combination would work better as chloroquine would be prevented from leaking out by a parallel action of primaquine that acts to block the pores on the surface of the parasite's digestive system The finding promises hope and would be less expensive when compared to the existing treatment. This would also ensure that it is made available the poorest countries where need is greatest.

However, caution has to be taken because primaquine is not suitable for all patients, as it could trigger the break down of red blood cells in people with an enzyme deficiency. People would have to be tested for the same before the therapy can be instituted.
'"/>




Page: 1

Related medicine news :

1. Abortion Pill approved by FDA
2. Another injectable contraceptive Pill approved by FDA
3. Levothyroxine Thyroid Hormone Replacement, Approved for Hypothyroidism
4. New FDA Approved Drug To Treat Migraine
5. Lose Weight With New Wonder Slimming FDA approved Prescription Drug
6. New FDA Approved Drug NATRECOR For Heart Failure Patients
7. Voice may be improved by surgery
8. New oral antiviral treatment of cold sores approved
9. Survival rates in breast cancer patients improved with "Dose Dense Chemotherapy"
10. ICU Survival can be improved by Antibiotic use
11. Survival rate not improved by invasive procedures
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/30/2017)... ... 2017 , ... Watch the video about the Revolution ... Organic Consumers Association, National Health Freedom Action, March Against Monsanto, The National Vaccine ... Moms Across America, Freedom and Ethics Alliance and the Vaccine Injury Awareness League ...
(Date:3/29/2017)... ... 29, 2017 , ... During the last week of March, Chad Kawa, MD ... individuals in the local community. , Colon cancer is the second leading cause ... cancer while it is small, confined and easier to treat. If you are 50 ...
(Date:3/29/2017)... (PRWEB) , ... March 30, 2017 , ... Grass pollen is the main cause of ... to the stuff. The season for grass pollen runs from May to July each year; ... hay fever victim to do? HayMax™ allergen barrier balms ( http://www.haymax.us ) provide an effective ...
(Date:3/29/2017)... ... March 29, 2017 , ... Wells Pharmacy Network, a ... at the upcoming World Congress, in Hollywood Florida April 6-8, 2017. , Ben ... the visionary leader in the training of physicians, scientists, and members of the ...
(Date:3/29/2017)... ... , ... Dr. Angela Cotey, a noted general dentist in Mt. Horeb, is ... or without a referral. Dr. Cotey knows that interceptive orthodontics in Mt. ... patients receive early treatment, they may achieve straight teeth with less treatment in their ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... NEW YORK , March 29, 2017 Global ... cross US$ 3 billion by 2021, growing at a CAGR ... containing iron prescribed by a doctor to treat anemia or ... the iron level in the body. However, in some cases, ... in the body and intravenous (IV) iron therapy comes into ...
(Date:3/29/2017)...  BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical ... based-therapies with a first in class collagenase-based product ...  in the U.S. and Xiapex ®  in Europe, today ... at the upcoming 16 th Annual Needham ... 8:00 a.m. ET in New York, ...
(Date:3/29/2017)... 29, 2017 Research and Markets has announced the ... Therapy Centers & Forecast" report to their offering. ... Proton Therapy Market in Italy ... value in 2016. There are currently three proton therapy centers in ... more patients. In Italy , the first patients were ...
Breaking Medicine Technology: